Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1719-1726

  Gandhi, Varsha ^a,b   Xu, Yi Zheng ^a,c   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOSYLURACIL 5' TRIPHOSPHATE; CYTARABINE; TETRAHYDRODEOXYURIDINE; TETRAHYDROURIDINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOACCUMULATION; CANCER RECURRENCE; CELL LEVEL; CYTOTOXICITY; DEAMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CYTARABINE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; URIDINE TRIPHOSPHATE;

EID: 0031799862     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Keating, M. J., McCredie, K. B., Bodey, G. P., Smith, T. L., Gehan, E. A., and Freireich, E. J. Improved prospects for long-term survival in adults with acute myelogenous leukemia. J. Am. Med. Assoc., 248: 2481-2486, 1982.
2. Chou, T-C., Arlin, Z., Clarkson, B. D., and Philips, F. S. Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res., 37: 3561-3570, 1977.
3. Schrecker, A. W., and Urshel, M. J. Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells. Cancer Res., 28: 793-801, 1968.
4. Early, A., Preisler, H. D., and Slocum, H. A pilot study of high-dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res., 42: 1587-1594, 1982.
5. Kantarjian, H. M., Estey, E. H., Plunkett, W., Keating, M. J., Walters, R. S., Iacoboni, S., McCredie, K. B., and Freireich, E. J. Phase I-II clinical and pharmacologic studies of high-dose 1-β-D-arabinofuranosylcytosine in refractory leukemia. Am. J. Med., 81: 387-394, 1986.
6. Estey, E. H., Keating, M. J., McCredie, K. B., Freireich, E. J., and Plunkett, W. Cellular ara-CTP pharmacokinetics, response and karyo-type in newly-diagnosed acute myelogenous leukemia. Leukemia (Baltimore), 4: 95-99, 1990.
7. Furth, J. J., and Cohen, S. S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res., 28: 2061-2067, 1968.
8. Townsend, A. J., and Cheng, Y-C. Sequence specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of chain elongation on a defined template. Mol. Pharmacol., 32: 330-339, 1987.
9. Kufe, D. W., Major, P. R., Egan, E. M., and Beardsley, P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-9000, 1980.
10. Major, P. P., Egan, E. M., Beardsley, G. P., Minden, G. P., and Kufe, D. W. Lethality of human myeloblasts correlated with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. USA, 78: 3235-3239, 1981.
11. Chabner, B. A. Cytidine analogues. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott-Raven, 1996.
12. Chabner, B. A., Johns, D. G., Coleman, C. N., Drake, J. S., and Evans, W. H. Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J. Clin. Investig., 53: 922-931, 1974.
13. Camiener, G. W., and Smith, C. G. Studies on the enzymatic deamination of 1-β-D-arabinofuranosylcytosine. I. Enzymatic distribution and species specificity. Biochem. Pharmacol., 14: 1405-1416, 1965.
14. Capizzi, R. L., Yong, J-L., Cheng, E., Bjorusson, T., Sahasrabudhe, D., Tan, R. S., and Cheng, Y-C. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J. Clin. Oncol., 1: 763-771, 1983.
15. Liliemark, J. O., Paul, C. Y., Gahrton, G., and Peterson, C. O. Pharmacokinetics of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-β-D-arabinofuranosylcytosine. Cancer Res., 45: 2373-2375, 1985.
16. Damon, L. E., Plunkett, W., and Linker, C. A. Plasma and cerebrospinal fluid pharmacokinetics of 1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosyluracil following the repeated intravenous administration of high and intermediate dose 1-β-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991.
17. Jamieson, G. P., Finch, L. R., Snook, M., and Wiley, J. S. Degradation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in human leukemic myeloblasts and lymphoblasts. Cancer Res., 47: 3130-3135, 1987.
18. Rcichard, P. Interactions between deoxyribonucleoside and DNA synthesis. Annu. Rev. Biochem., 57: 349-374, 1988.
19. Maley, G. F., and Maley, F. The purification and properties of deoxycytidylate deaminase from chick embryo extracts. J. Biol. Chem., 239: 1168-1176, 1964.
20. Nucci, R., Raia, C. A., Vaccaro, C., Rossi, M., and Whitehead, E. P. Allosteric modifier and substrate binding of donkey deoxycytidylate aminohydrolase. Arch. Biochem. Biophys., 289: 19-25, 1991.
21. Maley, F., and Maley, G. F. Nucleotide interconversions. II. Elevation of deoxycytidylate deaminase and thymidylate synthetase in regenerating rat liver. J. Biol. Chem., 235: 2968-2970, 1960.
22. Giusti, G., Mangoni, C., De Petrocellis, B., and Scarano, E. Deoxycytidylate deaminase and deoxycytidine deaminase in normal and neoplastic human tissues. Enzymol. Biol. Clin., 11: 375-383, 1970.
23. Ellims, P. H., and Medley, G. Deoxycytidylate deaminase activity in lymphoproliferative disorders. Leuk. Res., 8: 123-128, 1984.
24. Fridland, A., and Verhof, F. Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. Semin. Oncol., 14 (Suppl. 1): 262-268, 1987.
25. Gandhi, V., Estey, E., Du, M., Nowak, B. J., Keating, M. J., and Plunkett, W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin. Cancer Res., 1: 169-178, 1995.
26. Gandhi, V., Estey, E., Keating, M. J., Chucrallah, A., and Plunkett, W. Chlorodeoxyadenosine and 1-β-D-arabinofuranoxylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood, 87: 256-264, 1996.
27. Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H., and Keating, M. J. Saturation of 1-β-D-arabinosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinosylcytosine therapy. Cancer Res., 47: 3005-3011, 1987.
28. Plunkett, W., Hug, V., Keating, M. J., and Chubb, S. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res., 40: 588-591, 1980.
29. Neu, H. C., and Heppel, L. A. Nucleotide sequence analysis of polyribonucleotides by means of periodate oxidation followed by cleavage with an amine. J. Biol. Chem., 239: 2927-2934, 1964.
30. Gandhi, V., Danhauser, L., and Plunkett, W. Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemic cells by high performance liquid chromatography. J. Chromatogr., 413: 293-299, 1987.
31. Parker, W. B., Shaddix, S. C., Chang, C-H., White, E. C., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A., Secrist, J. A., III, and Bennett, L. L., Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
32. Gandhi, V., Huang, P., and Plunkett, W. Metabolism and action of arabinosyluracil 5′-triphosphate in acute myelogenous leukemia blasts. Proc. Am. Assoc. Cancer Res., 33: 545, 1992.
33. Muus, P., Drenthe-Schonk, A., Haanen, C., Linssen, P., and Wessels, H. In vitro studies on phosphorylation and dephosphorylation of 1-β-D-arabinofuranosylcytosine in human leukemic cells. Leuk. Res., 11: 319-325, 1987.
34. Shewach, D., Ensminger, W. D., and Hughes, T. L. Apparent substrate inhibition of deoxycytidine kinase. Proc. Am. Assoc. Cancer Res., 35: 425, 1994.
35. Riva, C. M., Rustum, Y. M., and Preisler, H. D. Pharmacokinetics and cellular determinants of response to 1-β-D-arabinofuranosylcytosine (ara-C). Semin. Oncol., 12 (Suppl. 3). 1-8, 1985.
36. Caradonna, S. J., and Cheng, Y-C. The role of deoxyuridine triphosphate nucleohydrolase, uracil DNA glycosylase, and DNA polymerase α in the metabolism of FUdR in human tumor cells. Mol. Pharmacol., 18: 513-520, 1980.
37. Canman, C. E., Lawrence, T. S., Shewach, D. S., Tang, H-Y., and Maybaum. J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphate activity and failure to accumulate deoxyuridine triphosphate. Cancer Res., 53: 5219-5224, 1993.
38. Ingraham, H. A., and Goulian, M. Deoxyuridine triphosphatase: a potential site of interaction with pyrimidine nucleotide analogues. Biochem. Biophys. Res. Commun., 109: 746-752, 1982.
39. Cohen, R. M., and Wolfenden, R. Cytidine deaminase from Escherichia coli Purification, properties, and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J. Biol. Chem., 246: 7561-7565, 1971.
40. Stoller, R. G., Myers, C. F., and Chabner, B. A. Analysis of cytidine deaminase and tetrahydrouridine interaction by the use of ligand techniques. Biochem. Pharmacol., 27: 53-59, 1978.
41. Heinemann, V., and Plunkett, W. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrouridine. Biochem. Pharmacol., 38: 4115-4121, 1989.
42. Maley, F., and Maley, G. F. Tetrahydrodeoxyuridylate: a potent inhibitor of deoxycytidylate deaminase. Arch. Biochem. Biophys., 144: 723-729, 1971.
43. Moran, R. G., Danenberg, P. V., and Heidelberger, C. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem. Pharmacol., 31: 2929-2935, 1982.
44. Mancini, W., and Cheng, Y-C. Human deoxycytidylate deaminase. Substrate and regulator specificities and their chemotherapeutic implications. Mol. Pharmacol., 23: 159-164, 1982.
45. Ellims, P., Kao, A. Y., and Chabner, B. A. Deoxycytidylate deaminase: purification and some properties of the enzyme isolated from human spleen. J. Biol. Chem., 256: 6335-6340, 1981.
46. Yang, J-L., Cheng, E. H., Capizzi, R. L., Cheng, Y-C., and Kute, T. Effect of uracil arabinoside on metabolism and cytotoxicity of 1-β-D-arabinofuranosylcytosine in L5178Y murine leukemia. J. Clin. Investig., 75: 141-146, 1985.
47. Gandhi, V., Chapman, A., Huang, P., and Plunkett, W. Sequence-specific inhibition of DNA polymerase a by 5′-triphosphates of 1-β-D-arabinofuranoxylcytosine and arabinosyluracil. Proc. Am. Assoc. Cancer Res., 34: 349, 1993.
48. Müller, W. E. G., and Zahn, R. K. Metabolism of 1-β-D-arabinofuranosyluracil in mouse L5178 cells. Cancer Res., 39: 1102-1107, 1979.
49. Ono, K., Ohashi, A., Ogasawara, M., Matsukage, A., Takahashi, T., Nakayama, A. C., and Saneyoshi, M. Inhibition of deoxyribonucleic acid polymerases from murine cells and oncovirus by 5-alkyl derivatives of 1-β-D-arabinofuranosyluracil 5′-triphosphate: substituent effects on inhibitory action. Biochemistry, 20: 5088-5093, 1981.
50. White, J. C., and Hines, L. H. Role of uridine triphosphate in the phosphorylation of 1-β-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells. Cancer Res., 47: 1820-1824, 1987.